Peripheral blood stem cells (PBSC) are an alternative source of progenitor cells which are being increasingly used in hematopoietic transplantation instead of bone marrow. We compared the use of low-dose G-CSF (50 g/m 2 /day), following salvage chemotherapy, efficient PBSC mobilization combined with chemotherapy remains unknown, although 5 g/kg/day has been con-(IAPVP-16) and G-CSF 5 g/kg/day (group A, n = 15) or 50 g/m 2 /day (group B, n = 15) from day 6 until the sidered the standard G-CSF dose.
/day). Thirty adult patients with relapsed or
enhances this mobilization. 3 Nevertheless, the optimal chemotherapeutic regimen and the dose of G-CSF for refractory lymphoma were treated with ifosfamide, VP-16, intermediate-dose Ara-C, methylprednisolone efficient PBSC mobilization combined with chemotherapy remains unknown, although 5 g/kg/day has been con-(IAPVP-16) and G-CSF 5 g/kg/day (group A, n = 15) or 50 g/m 2 /day (group B, n = 15) from day 6 until the sidered the standard G-CSF dose.
2,4,5
The present study was aimed at comparing the hematolend of leukaphereses. The duration of neutropenia and thrombocytopenia were equal in both groups. A median ogical recovery and PBSC-mobilizing potential of low-dose G-CSF after ifosfamide, VP-16, intermediate-dose Ara-C, of two (1-3) leukaphereses were performed in both groups to harvest Ͼ3.5 ؋ 10 6 /kg CD34 ؉ cells. The nummethylprednisolone (IAPVP-16) salvage chemotherapy in comparison with a historical control group who received a bers of circulating CD34
؉ cells on the first day of leukocyte recovery were similar in both groups in those standard dose of G-CSF (5 g/kg/day). patients mobilized after a first cycle of IAPVP-16. The numbers of circulating CD34 ؉ cells were similar in patients mobilized after a first and after a second Patients and methods IAPVP-16 in group A. In the low-dose group (group B), however, the numbers of circulating CD34
؉ cells Thirty patients with relapsed or refractory non-Hodgkin's lymphoma (n = 27) and Hodgkin's disease (n = 3) were significantly lower in those mobilized after a second than after a first course. Additionally, the prounderwent PBSC harvest after salvage chemotherapy with the IAPVP-16 protocol followed by G-CSF. ؉ cells after a first cycle of IAPVP-16 of two (1-3) courses per patient were given and a time interval of 28 days between courses. In patients with bone salvage chemotherapy, resulting in a substantial decrease in costs, while more heavily pretreated marrow infiltration pre-IAPVP-16, PBSC were harvested after the second course in an effort to decrease the tumor patients may require higher doses of G-CSF for an equivalent mobilization.
contamination of the graft. There were no significant differences between the pretreatment characteristics of both Keywords: G-CSF; chemotherapy; PBSC mobilization; lymphoma patient groups.
PBSC mobilization and collection
Patients received salvage chemotherapy with the IAPVP-16 protocol, which includes: ifosfamide 5 g/m 2 i.v. on day 
Results

Characteristics Group A Group B
In group A, PBSC collection was performed after a first
(n = 6) or second (n = 9) course of IAPVP-16, while in
group B, PBSC were collected after the first (n = 6), second (n = 8) or third (n = 1) course of IAPVP-16. and 52 × 10 6 /l (10.2 × 10 6 -114 × 10 6 ) in patients mobilized
Number of previous chemotherapy regimens after the second course (n = 9)(P = NS). In group B, a A or group B. The number of CD34 + cells collected with the first leukapheresis were analyzed in order to evaluate further the mobilization potential of both dose schedules. In group A, the median numbers of CD34 + cells collected after the first apheresis were 4.58 × 10 6 /kg (4.22-75.8) and Thousand Oaks, CA, USA) was given as a single daily sub-8.9 × 10 6 /kg (0.92-17.2) for patients mobilized after a first cutaneous injection from day 6 from the start of chemoor second cycle of chemotherapy, respectively (P = NS). therapy until the end of leukaphereses at the doses stated
In group B, the corresponding values were 16.98 × 10 6 /kg above.
(7.88-42.84) and 5.07 × 10 6 /kg (0.93-9.06), respectively Leukaphereses were performed daily over subsequent (Table 2 ) (P = 0.003). days when the patients reached more than 1 × 10 9 WBC/l The total number of harvested cells depended on the and 2.5 × 10 6 CD34 + cells/l of peripheral blood. MNCs amount of circulating progenitors and the number of leuwere collected by a continuous-flow blood cell separator kaphereses performed. A median total number of COBE Spectra (Lakewood, CO, USA) (n = 19 in group A, 4.06 × 10 8 /kg MNC (1-7.15), 59.6 × 10 4 /kg CFU-GM n = 6 in group B) or Fenwal CS-3000 Plus (Baxter, Barce-(4.04-306.3) and 10.2 × 10 6 /kg CD34 + cells (3.84-75.87) lona, Spain) (n = 8 in group A, n = 21 in group B). A were collected in group A, and a median number of median volume of 15 liters (8-23) was processed per apher-2.29 × 10 8 /kg MNC (0.92-10.65), 12.56 × 10 4 /kg CFU-GM esis in both groups with a flow rate of 60-100 ml/min. Aph-(1.92-80.32) and 11.91 × 10 6 CD34 + cells (3.71-42.84) in ereses were performed until a minimum of 3.5 × 10 6 /kg group B. There were no significant differences in the total CD34 + cells were collected. Each leukapheresis product numbers of harvested MNC, CD34 + cells and CFU-GM. was cryopreserved in liquid nitrogen 6 until the day of transThe mobilization protocol was well tolerated. The plantation.
median duration of neutropenia (Ͻ0.5 × 10 9 /l) was 5 (1-6) days in group A and 5 (2-8) days in group B. The median In vitro assays Table 2 Characteristics of the first leukapheresis in both patient duration of thrombocytopenia (Ͻ20 × 10 9 /l) was 2 (0-5) changes that may alter the routine work of the stem cell pheresis unit and stem cell processing laboratory. Finally, days in group A and 1 (0-4) day in group B. Non-hematologic toxicities were well tolerated in both groups. There the reduction of the daily dose of G-CSF from about 200 g/m 2 day to 50 g/m 2 /day, when given for a median were 11 episodes of neutropenic fever in group A and eight cases in group B and one and four cases of grade 2 neuroof 8 days per cycle (days 6-13), would save 1200 g/m 2 per cycle. At a current cost of US$39 per 100 g of filgraslogic toxicity, respectively. tim in our country, this lower dose would reduce the cost of G-CSF per cycle by US$840 in an adult with a body surface area of 1.8 m 2 . Our results, of course, do not necesDiscussion sarily apply to other patient groups and/or other chemotherapy regimens or growth factors, since many variables The combination of chemotherapy plus G-CSF is superior to chemotherapy or G-CSF alone for the mobilization of have been shown to have an impact on the ability to collect adequate amounts of PBSC in different settings.
4,8,17
PBSC 8,9 and offers the possibility of both treating the underlying disease and obtaining cells for a possible later
In conclusion, our results suggest that a low dose of G-CSF can mobilize an equivalent number of PBSC following high-dose intensification. We previously reported that the IAPVP-16 protocol followed by standard-dose G-CSF is a a first cycle of the IAPVP-16 salvage chemotherapy regimen as the standard dose, and that both dose schedules are very effective mobilizing regimen in patients with advanced lymphoma. 10 In most reported studies the dose of G-CSF equally effective in shortening the period of severe neutropenia, thus lowering the expense of the use of this growth varies from 2.5 to 24 g/kg/day, 8,9,11 but few studies have evaluated the efficacy of low doses of G-CSF. 12, 13 Our factor. Mobilization after later cycles of IAPVP-16, however, may require higher doses of G-CSF, thus suggesting results suggest that low-dose G-CSF (50 g/m 2 /day) accelerates neutrophil recovery similarly to a standard dose that a dose-response relationship for the mobilization of PBSC exists mainly in more heavily pretreated patients. (5 g/kg/day), as previously reported in other settings. [12] [13] [14] However, the mobilization potential of the low dose appears to be lower in patients who are mobilized after a second cycle of IAPVP-16, as measured by smaller counts References of circulating CD34
+ cells and less progenitors harvested with the first leukapheresis. Nevertheless, the mobilization as soon as possible during a salvage programme. 4 hold, large amounts of precursors were harvested after a mobilization was very reproducible in our cases (day 13 or
